ACTILYSE TREATMENT SET Infusion

What is ACTILYSE TREATMENT SET

ACTILYSE TREATMENT SET is a pharmaceutical product used as a thrombolytic agent to dissolve blood clots in acute medical emergencies. It contains Alteplase, a recombinant human tissue-type plasminogen activator (rt-PA), supplied as two vials each containing 50mg of alteplase powder along with two 50ml solvents and an administration kit. This preparation is primarily indicated for intravenous infusion to treat conditions caused by blood clots obstructing blood vessels.

• Primarily used in acute ischemic stroke, acute myocardial infarction (heart attack), and pulmonary embolism to restore blood flow.
• Helps reduce long-term disability after stroke by rapidly dissolving clots.
• Acts as a life-saving therapy in emergency settings where rapid reperfusion of occluded vessels is critical.
• Administered under strict medical supervision, typically in hospitals or emergency care units.
• Provided as a ready-to-reconstitute powder with a solvent and administration kit for intravenous use.

ACTILYSE is a vital intervention in managing thrombotic conditions where timely clot breakdown can significantly improve patient outcomes.

How to use ACTILYSE TREATMENT SET

ACTILYSE must be administered carefully and only by trained healthcare professionals due to its potent effects and risks. The key usage guidelines include:

• Preparation: Reconstitute the alteplase powder with the provided sterile solvent to form a clear solution.
• Administration: Given as an intravenous infusion via a central or peripheral vein using the supplied kit.
• Dosing regimen: Dosage and infusion rate depend on the indication (e.g., stroke, myocardial infarction) and patient’s weight.
• Timing: Must be started as soon as possible within the recommended time window from symptom onset, generally within 3 to 4.5 hours for ischemic stroke.
• Monitoring: Continuous monitoring of vital signs, coagulation parameters, and neurological status during and after infusion is essential.
• Contraindications and precautions: Carefully evaluate patient history for bleeding risks before administration.
• Post-infusion care: Avoid invasive procedures for at least 24 hours post-treatment to reduce bleeding risks.

Strict adherence to clinical protocols ensures maximal therapeutic benefit while minimizing complications.

Mode of Action ACTILYSE TREATMENT SET

ACTILYSE contains alteplase, a recombinant tissue plasminogen activator (rt-PA), whose mechanism involves:

• Fibrin binding: Alteplase selectively binds to fibrin within a thrombus (blood clot), localizing its activity to the site of the clot.
• Plasminogen activation: Converts plasminogen to plasmin, an enzyme that enzymatically breaks down fibrin clots into soluble degradation products.
• Clot dissolution: By lysing fibrin, it effectively dissolves the thrombus, restoring blood flow in occluded arteries or veins.
• Selective action: Its fibrin specificity reduces systemic plasminogen activation, thereby limiting unwanted bleeding elsewhere.
• Rapid onset: Provides timely reperfusion in ischemic tissues, critical for saving cells in organs like the brain and heart.

The targeted enzymatic action of alteplase underlies its role as a life-saving thrombolytic agent in acute vascular occlusions.

ACTILYSE TREATMENT SET Interactions ACTILYSE TREATMENT SET

Several important drug interactions must be considered when using ACTILYSE to avoid increased bleeding risk or reduced efficacy:

• Anticoagulants (e.g., warfarin, heparin): Concomitant use significantly increases bleeding risk; careful monitoring and dose adjustment required.
• Antiplatelet agents (e.g., aspirin, clopidogrel): May potentiate bleeding tendencies; used cautiously depending on clinical scenario.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Increase bleeding risk when combined with thrombolytics.
• Other thrombolytics or fibrinolytics: Avoid concurrent use due to additive bleeding risk.
• Drugs affecting coagulation or platelet function: Any agents influencing coagulation should be carefully reviewed before ACTILYSE administration.
• Interactions with cytochrome P450 substrates: Minimal, as alteplase is a protein-based drug primarily cleared by proteolysis.

Close coordination between healthcare providers is essential to manage potential interactions and ensure patient safety.

Dosage of ACTILYSE TREATMENT SET

Dosage of ACTILYSE depends on the indication and patient-specific factors, particularly weight and timing of administration:

• Acute Ischemic Stroke: Recommended dose is 0.9 mg/kg body weight (maximum 90 mg), administered as a 10% bolus over 1 minute followed by the remaining 90% infused over 60 minutes.
• Acute Myocardial Infarction: Dosing varies by protocol, often 100 mg infused over 1.5 to 2 hours; tailored by patient weight and clinical status.
• Pulmonary Embolism: Dose usually 100 mg infused over 2 hours; adjustments per clinical guidelines.
• Other Indications: Dosage and infusion rate should follow approved clinical protocols or physician discretion.
• Special Populations: Dosage adjustments in elderly or patients with bleeding risks may be necessary; clinical judgment paramount.

Correct dosing and timely administration are critical for achieving desired thrombolytic effects while minimizing hemorrhagic complications.

Possible side effects of ACTILYSE TREATMENT SET

While ACTILYSE is life-saving, it carries a risk of serious adverse effects primarily related to bleeding:

• Major Bleeding: Intracranial hemorrhage is the most feared complication; other serious bleeding can occur at sites of invasive procedures, mucosal surfaces, or gastrointestinal tract.
• Minor Bleeding: Includes bruising, nosebleeds, gum bleeding, and puncture site hemorrhage.
• Allergic Reactions: Rare but possible including rash, itching, and anaphylaxis.
• Hypotension: Can occur during infusion; requires monitoring.
• Fever and Nausea: Occasionally reported.
• Other Effects: Possible reperfusion arrhythmias in myocardial infarction, although uncommon.

Because of bleeding risks, patients must be carefully selected and closely monitored during and after treatment.

ACTILYSE TREATMENT SET Contraindications ACTILYSE TREATMENT SET

ACTILYSE should not be used in patients with the following contraindications to avoid life-threatening complications:

• Active internal bleeding or recent hemorrhagic stroke.
• History of intracranial hemorrhage, cerebral aneurysm, or arteriovenous malformation.
• Severe uncontrolled hypertension (e.g., systolic >185 mmHg or diastolic >110 mmHg).
• Recent major surgery, trauma, or head injury within previous 3 months.
• Known bleeding diathesis or coagulopathy.
• Use of anticoagulants with elevated coagulation tests unless benefits outweigh risks.
• Pregnancy, unless potential benefits justify risks.

Proper patient evaluation is crucial to minimize the risk of catastrophic bleeding events.

Storage of ACTILYSE TREATMENT SET

To maintain stability and effectiveness, ACTILYSE must be stored under specific conditions:

• Store the lyophilized alteplase vials and solvents at 2°C to 8°C (refrigerated).
• Protect from light and moisture by keeping vials in their original packaging until use.
• Do not freeze; freezing can inactivate the protein.
• After reconstitution, use the solution immediately or within recommended time frames (generally within 8 hours under refrigeration if necessary).
• Keep out of reach of children.
• Check expiration date before use; do not use expired products.

Proper storage ensures the safety and efficacy of ACTILYSE when administered to patients.